Emalex raises $250m for Tourette syndrome drug development
Pharmaceutical Technology
NOVEMBER 3, 2022
Emalex Biosciences has raised Series D funds worth $250m led by Bain Capital Life Sciences to progress the development of an investigational new drug for Tourette syndrome. Additionally, trial subjects did not have adverse movement or metabolic side effects usually seen with antipsychotic agents.
Let's personalize your content